A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas?

Carolyn R. Freeman, Jim Kepner, Larry E. Kun, Robert A. Sanford, Richard Kadota, Lynda Mandell, Henry Friedman

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: To compare the proportion of patients that survive at least 1 year following treatment with hyperfractionated radiotherapy (HRT) to a dose of 70.2 Gy on Pediatric Oncology Group (POG) study 8495 with that of patients treated with similar radiotherapy plus cisplatinum given by continuous infusion on weeks 1, 3, and 5 of radiotherapy on POG 9239. Methods and Materials: The eligibility criteria for the two studies were identical and included age 3 to 21 years, previously untreated tumor involving the brain stem of which two-thirds was in the pons, history less than 6 months, and clinical findings typical for diffuse intrinsic brain stem glioma, including cranial nerve deficits, long tract signs, and ataxia. The outcome of 57 patients who were treated at the 70.2 Gy dose level of POG 8495 between May 1986 and February 1988 was compared with that of 64 patients treated with identical radiotherapy plus cisplatinum on POG 9239 between June 1992 and March 1996. Results: The number of patients accrued to POG 9239 was determined to guarantee that the probability was at least 0.80 of correctly detecting that the 1-year survival rate exceeded that of patients on POG 8495 by 0.2. However, the z value for this test was -1.564, giving a p value of 0.9411. That is, there is almost sufficient evidence to conclude that survival for patients receiving HRT plus cisplatinum on POG 9239 was worse than that for patients receiving the same radiotherapy alone on POG 8495. Conclusion: The finding that patients who received cisplatinum given as a radiosensitizing agent concurrent with HRT fared less well than those receiving the same dose of HRT alone was unexpected and is clearly a cause for concern as many current protocols for patients with diffuse intrinsic brain stem gliomas call for use of chemotherapeutic and/or biological agents given concurrent with radiotherapy. (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)561-564
Number of pages4
JournalInternational Journal of Radiation Oncology Biology Physics
Volume47
Issue number3
DOIs
StatePublished - Jun 1 2000

Fingerprint

brain stem
chemotherapy
Glioma
Brain Stem
radiation therapy
Radiotherapy
Drug Therapy
Pediatrics
dosage
ataxia
Brain Stem Neoplasms
Radiation-Sensitizing Agents
Pons
Cranial Nerves
Biological Factors
nerves
Ataxia
proportion
tumors
Survival Rate

Keywords

  • Brain stem tumors
  • Chemotherapy
  • Radiotherapy
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? / Freeman, Carolyn R.; Kepner, Jim; Kun, Larry E.; Sanford, Robert A.; Kadota, Richard; Mandell, Lynda; Friedman, Henry.

In: International Journal of Radiation Oncology Biology Physics, Vol. 47, No. 3, 01.06.2000, p. 561-564.

Research output: Contribution to journalArticle

Freeman, Carolyn R. ; Kepner, Jim ; Kun, Larry E. ; Sanford, Robert A. ; Kadota, Richard ; Mandell, Lynda ; Friedman, Henry. / A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas?. In: International Journal of Radiation Oncology Biology Physics. 2000 ; Vol. 47, No. 3. pp. 561-564.
@article{b8762b1db63744f69a94fce5172d3d8b,
title = "A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas?",
abstract = "Purpose: To compare the proportion of patients that survive at least 1 year following treatment with hyperfractionated radiotherapy (HRT) to a dose of 70.2 Gy on Pediatric Oncology Group (POG) study 8495 with that of patients treated with similar radiotherapy plus cisplatinum given by continuous infusion on weeks 1, 3, and 5 of radiotherapy on POG 9239. Methods and Materials: The eligibility criteria for the two studies were identical and included age 3 to 21 years, previously untreated tumor involving the brain stem of which two-thirds was in the pons, history less than 6 months, and clinical findings typical for diffuse intrinsic brain stem glioma, including cranial nerve deficits, long tract signs, and ataxia. The outcome of 57 patients who were treated at the 70.2 Gy dose level of POG 8495 between May 1986 and February 1988 was compared with that of 64 patients treated with identical radiotherapy plus cisplatinum on POG 9239 between June 1992 and March 1996. Results: The number of patients accrued to POG 9239 was determined to guarantee that the probability was at least 0.80 of correctly detecting that the 1-year survival rate exceeded that of patients on POG 8495 by 0.2. However, the z value for this test was -1.564, giving a p value of 0.9411. That is, there is almost sufficient evidence to conclude that survival for patients receiving HRT plus cisplatinum on POG 9239 was worse than that for patients receiving the same radiotherapy alone on POG 8495. Conclusion: The finding that patients who received cisplatinum given as a radiosensitizing agent concurrent with HRT fared less well than those receiving the same dose of HRT alone was unexpected and is clearly a cause for concern as many current protocols for patients with diffuse intrinsic brain stem gliomas call for use of chemotherapeutic and/or biological agents given concurrent with radiotherapy. (C) 2000 Elsevier Science Inc.",
keywords = "Brain stem tumors, Chemotherapy, Radiotherapy, Treatment",
author = "Freeman, {Carolyn R.} and Jim Kepner and Kun, {Larry E.} and Sanford, {Robert A.} and Richard Kadota and Lynda Mandell and Henry Friedman",
year = "2000",
month = "6",
day = "1",
doi = "10.1016/S0360-3016(00)00471-5",
language = "English (US)",
volume = "47",
pages = "561--564",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas?

AU - Freeman, Carolyn R.

AU - Kepner, Jim

AU - Kun, Larry E.

AU - Sanford, Robert A.

AU - Kadota, Richard

AU - Mandell, Lynda

AU - Friedman, Henry

PY - 2000/6/1

Y1 - 2000/6/1

N2 - Purpose: To compare the proportion of patients that survive at least 1 year following treatment with hyperfractionated radiotherapy (HRT) to a dose of 70.2 Gy on Pediatric Oncology Group (POG) study 8495 with that of patients treated with similar radiotherapy plus cisplatinum given by continuous infusion on weeks 1, 3, and 5 of radiotherapy on POG 9239. Methods and Materials: The eligibility criteria for the two studies were identical and included age 3 to 21 years, previously untreated tumor involving the brain stem of which two-thirds was in the pons, history less than 6 months, and clinical findings typical for diffuse intrinsic brain stem glioma, including cranial nerve deficits, long tract signs, and ataxia. The outcome of 57 patients who were treated at the 70.2 Gy dose level of POG 8495 between May 1986 and February 1988 was compared with that of 64 patients treated with identical radiotherapy plus cisplatinum on POG 9239 between June 1992 and March 1996. Results: The number of patients accrued to POG 9239 was determined to guarantee that the probability was at least 0.80 of correctly detecting that the 1-year survival rate exceeded that of patients on POG 8495 by 0.2. However, the z value for this test was -1.564, giving a p value of 0.9411. That is, there is almost sufficient evidence to conclude that survival for patients receiving HRT plus cisplatinum on POG 9239 was worse than that for patients receiving the same radiotherapy alone on POG 8495. Conclusion: The finding that patients who received cisplatinum given as a radiosensitizing agent concurrent with HRT fared less well than those receiving the same dose of HRT alone was unexpected and is clearly a cause for concern as many current protocols for patients with diffuse intrinsic brain stem gliomas call for use of chemotherapeutic and/or biological agents given concurrent with radiotherapy. (C) 2000 Elsevier Science Inc.

AB - Purpose: To compare the proportion of patients that survive at least 1 year following treatment with hyperfractionated radiotherapy (HRT) to a dose of 70.2 Gy on Pediatric Oncology Group (POG) study 8495 with that of patients treated with similar radiotherapy plus cisplatinum given by continuous infusion on weeks 1, 3, and 5 of radiotherapy on POG 9239. Methods and Materials: The eligibility criteria for the two studies were identical and included age 3 to 21 years, previously untreated tumor involving the brain stem of which two-thirds was in the pons, history less than 6 months, and clinical findings typical for diffuse intrinsic brain stem glioma, including cranial nerve deficits, long tract signs, and ataxia. The outcome of 57 patients who were treated at the 70.2 Gy dose level of POG 8495 between May 1986 and February 1988 was compared with that of 64 patients treated with identical radiotherapy plus cisplatinum on POG 9239 between June 1992 and March 1996. Results: The number of patients accrued to POG 9239 was determined to guarantee that the probability was at least 0.80 of correctly detecting that the 1-year survival rate exceeded that of patients on POG 8495 by 0.2. However, the z value for this test was -1.564, giving a p value of 0.9411. That is, there is almost sufficient evidence to conclude that survival for patients receiving HRT plus cisplatinum on POG 9239 was worse than that for patients receiving the same radiotherapy alone on POG 8495. Conclusion: The finding that patients who received cisplatinum given as a radiosensitizing agent concurrent with HRT fared less well than those receiving the same dose of HRT alone was unexpected and is clearly a cause for concern as many current protocols for patients with diffuse intrinsic brain stem gliomas call for use of chemotherapeutic and/or biological agents given concurrent with radiotherapy. (C) 2000 Elsevier Science Inc.

KW - Brain stem tumors

KW - Chemotherapy

KW - Radiotherapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0034213898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034213898&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(00)00471-5

DO - 10.1016/S0360-3016(00)00471-5

M3 - Article

C2 - 10837936

AN - SCOPUS:0034213898

VL - 47

SP - 561

EP - 564

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -